deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03483103

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Sponsor: Juno Therapeutics, a Subsidiary of Celgene

Conditions Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoma, Nonhodgkin
Interventions lisocabtagene maraleucel
Updated 26 times since 2018 Last updated: Nov 28, 2023 Started: Jul 27, 2018 Primary completion: Sep 24, 2021 Completion: Dec 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma, B-Cell and Lymphoma, Large B-Cell, Diffuse, this trial is completed. The trial is conducted by Juno Therapeutics, a Subsidiary of Celgene and has accumulated 26 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Apr 2019 · 59 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2022 · 14 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~Jan 2024 · 11 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

26 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Feb 2023 — Jan 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. May 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 21 earlier versions

  1. Mar 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  4. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  5. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  6. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  7. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  8. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  9. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  10. Nov 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  11. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  12. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  13. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  14. Jun 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  15. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  16. Feb 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

  17. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE2

  18. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  19. Jul 2018 — Aug 2018 [monthly]

    Not Yet Recruiting PHASE2

  20. Jun 2018 — Jul 2018 [monthly]

    Not Yet Recruiting PHASE2

  21. Apr 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Juno Therapeutics, a Subsidiary of Celgene
Data source: Juno Therapeutics, a Subsidiary of Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Atlanta, United States , Baltimore, United States , Charlotte, United States , Chicago, United States , Cincinnati, United States , Dallas, United States , East Brunswick, United States , Gilbert, United States , Greenville, United States and 12 more locations